Orforglipron
Orforglipron is a pharmaceutical drug with 36 clinical trials. Currently 16 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
0
Mid Stage
29
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
16 of 16 finished
0.0%
0 ended early
16
trials recruiting
36
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Clinical Trials (36)
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 36